Physician profile
Mojca Lorbar
NPI 1881681187
$728.80
in general payments reported to CMS, 2019-2025
13 companies · $82.81 in 2025
The $82.81 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $138 · 2022: $21.70 · 2024: $56.18 · 2025: $82.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $143.29 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $109.48 | 2019-2020 | |
| Amgen INC. | $100.78 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $66.13 | 2019 | |
| Amarin Pharma, INC. | $64.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $54.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.87 | 2020 | |
| Preventice Services, LLC | $37.00 | 2019-2020 | |
| Pfizer INC. | $27.74 | 2019-2020 | |
| Lundbeck LLC | $22.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.32 | 2019 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.32 | 2025 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mojca Lorbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.